Clin Exp Allergy:无症状HDM敏感和HDM过敏性鼻炎患者的临床和免疫学差异

2019-02-26 AlexYang MedSci原创

对敏感症的临床相关性确定对过敏性鼻炎的诊断非常重要。最近,有研究人员调查了体外嗜碱性细胞活化试验和溶解组分诊断在区分症状性过敏性鼻炎患者和对室内尘螨(HDMs)无症状敏感患者中的使用价值。研究包括了66名HDM皮肤针刺试验阳性患者,并基于他们的临床历史和鼻激发测试分为症状组(n=17)和无症状组(n=19)。研究人员评估了嗜碱性CD63响应对体外过敏原屋尘螨全提取物刺激的响应和lgE对Der p

对敏感症的临床相关性确定对过敏性鼻炎的诊断非常重要。最近,有研究人员调查了体外嗜碱性细胞活化试验和溶解组分诊断在区分症状性过敏性鼻炎患者和对室内尘螨(HDMs)无症状敏感患者中的使用价值。

研究包括了66名HDM皮肤针刺试验阳性患者,并基于他们的临床历史和鼻激发测试分为症状组(n=17)和无症状组(n=19)。研究人员评估了嗜碱性CD63响应对体外过敏原屋尘螨全提取物刺激的响应和lgE对Der p 1, 2, 4, 5, 7, 10, 11, 14, 15, 18, 21, 23的反应情况。另外,研究人员还测量了屋尘螨全过敏原提取物特异性的血清lgE和lgG水平情况。研究发现,lgE水平(lgE水平在症状性患者中更高,p=0.055)、屋尘螨特异性lgG和总lgE均没有显著的差异。与无症状患者相比,症状性患者对体外嗜碱性激活表现出了更低的阈值(3.33 ng/mL vs. 33.3 ng/mL)、更高的嗜碱性激活曲线(AUC)面积(p=0.017)、对anti-FcεRI刺激阳性对照更高的响应(97% vs. 79%) (P<0.001)、识别更多的HDM过敏原(4 vs. 2)、对rDer p 7 (P=0.016)和rDer p 23(P=0.018)更高的频率的敏感性。另外,识别过敏原的数量与嗜碱性激活AUC具有正相关关系(r=0.63; P<0.001)。

最后,研究人员指出,识别的HDM过敏原数量和对rDer p 7和rDer p 23的反应性是区分无症状HMD和症状性HDM患者的有效方式,并且比SPT或者过敏原提取特异性lgE效果更好。另外,敏感征的临床相关性信息对过敏原特异性免疫治疗也非常重要。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889421, encodeId=8f13188942156, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Mar 31 02:01:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047080, encodeId=4d51204e080e5, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 05 14:01:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329211, encodeId=1f501329211b3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485029, encodeId=eb7f14850290b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889421, encodeId=8f13188942156, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Mar 31 02:01:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047080, encodeId=4d51204e080e5, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 05 14:01:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329211, encodeId=1f501329211b3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485029, encodeId=eb7f14850290b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889421, encodeId=8f13188942156, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Mar 31 02:01:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047080, encodeId=4d51204e080e5, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 05 14:01:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329211, encodeId=1f501329211b3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485029, encodeId=eb7f14850290b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-02-28 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889421, encodeId=8f13188942156, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Mar 31 02:01:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047080, encodeId=4d51204e080e5, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 05 14:01:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329211, encodeId=1f501329211b3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485029, encodeId=eb7f14850290b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Feb 28 04:01:00 CST 2019, time=2019-02-28, status=1, ipAttribution=)]

相关资讯

Saudi Med J:焦虑性格在过敏性鼻炎患者中的影响研究

最近,有研究人员评估了过敏性鼻炎患者中的抑郁和焦虑水平,并调查了抑郁和焦虑症状与抑郁和焦虑性格之间的关系。研究是代表性的,在2017年和2018年之间进行,包括了101名AR患者和74名健康对照。研究人员对所有参与者进行了贝克抑郁症量表(BDI)、贝克焦虑量表(BAI)和TEMPS-A评估。研究发现,患者的BAI和BDI得分均值鼻对照组显著更高(p=0.016和p=0.001)。在AR患者中,抑郁

J Asthma:中度到重度永久过敏性鼻炎对胸腹运动学与呼吸肌功能影响研究

最近,有研究人员评估了中度到重度永久过敏性鼻炎患者中胸腹运动学、呼吸肌力和膈肌肌电图活性(EAdi)。研究是一个代表性的研究,包括了40名参与者,20名为AR患者,20名为对照。研究发现,AR患者的胸腹运动学受损(胸壁总体积减少)(p=0.004),总呼吸周期(p=0.014)和呼气时间值(P=0.006)均更低。另外,AR患者的腹壁肋骨贡献百分比(p=0.475)和呼吸速率(p=0.019)均增

Am J Rhinol Allergy:轻度到中度常年性变应性鼻炎儿童患者中鼻内纤维素粉治疗对哮喘的控制效果研究

常年性变应性鼻炎(PAR)常存在于哮喘患者中。据报道,鼻内纤维素粉(ICP)在改善PAR中是有效的。最近,有研究人员在患有过敏性哮喘(AA)的PAR儿童中,调查了是否ICP与鼻内糖皮质激素在改善哮喘控制和鼻症状方面效果的相当的。研究是一个单中心、随机、安慰剂-对照的试验,进行的时间为2015年7月到2016年9月之间。研究包括了121名患者(A组、B组和C组人数分别为38、41和42),分别进行的

J Leukoc Biol:过敏性鼻炎患者中,白介素-5能够诱导CD4+T细胞凋亡缺陷

辅助性T细胞(Th)2极化在过敏性疾病的病理中具有重要的角色,而潜在的机制仍旧需要进一步的调查。类B细胞淋巴瘤蛋白-2蛋白12(Bcl2L12)具有抗凋亡的功能。最近,有研究人员阐释了过敏性鼻炎(AR)患者中,Bcl2L12对Th2极化的影响。研究发现,AR CD4+ T细胞(来源于AR患者)展现出了细胞凋亡的缺陷。FasL在AR CD4+ T细胞中表达要比HC(健康对照) CD4+ T细胞中更低

盘点:近期鼻疾病盘点

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Rhinology:在非过敏性鼻炎中,干冷空气激发是一种可靠的诊断工具 https://www.ncbi.nlm.nih.gov/pubmed/30609423对非过敏性鼻

Allergy:青少年中关于DNA甲基化和过敏性敏感的基因组纵向研究

过敏性敏感的存在对儿童常见的哮喘和鼻炎的发展具有重要的影响。过敏性敏感的病因仍旧不清楚,并且其潜在的机制还没有建立。一些研究表明一些CpGs的DNA甲基化(DNAm)与过敏性敏感相关。然而,尚没有研究关注青少年时期。最近,有研究人员使用线性混合模型评估了青春期前后全基因组DNAm与室内、室外和食物过敏原过敏敏感之间相关性。研究发现,通过线性混合模型,鉴定了35个CpGs与过敏性敏感相关(错误发现率